VAMAS6
MCID: VTL009
MIFTS: 42

Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6 (VAMAS6)

Categories: Genetic diseases, Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

MalaCards integrated aliases for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:

Name: Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6 56 13
Generalized Vitiligo 73 71
Vitiligo 73 71
Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 71
Vamas6 56
Vtlg 73

Characteristics:

OMIM:

56
Inheritance:
? epistatically interacting multiple autosomal recessive


HPO:

31
vitiligo-associated multiple autoimmune disease susceptibility 6:
Inheritance autosomal recessive inheritance


Classifications:



External Ids:

OMIM 56 193200
MeSH 43 D014820
UMLS 71 C0042900 C1304470 C1847835

Summaries for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

UniProtKB/Swiss-Prot : 73 Vitiligo: A pigmentary disorder of the skin and mucous membranes. It is characterized by circumscribed depigmented macules and patches, commonly on extensor aspects of extremities, on the face or neck and in skin folds. Vitiligo is a progressive disorder in which some or all of the melanocytes in the affected skin are selectively destroyed. It is a multifactorial disorder with a complex etiology probably including autoimmune mechanisms, and is associated with an elevated risk of other autoimmune diseases.

MalaCards based summary : Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6, also known as generalized vitiligo, is related to vitiligo-associated multiple autoimmune disease susceptibility 1 and deafness, congenital, with vitiligo and achalasia, and has symptoms including pruritus and exanthema. An important gene associated with Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6 is PTPN22 (Protein Tyrosine Phosphatase Non-Receptor Type 22). The drugs Pimecrolimus and mometasone furoate have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and thyroid, and related phenotypes are vitiligo and nevus

More information from OMIM: 193200

Related Diseases for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Diseases in the Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 family:

Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Diseases related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 612)
# Related Disease Score Top Affiliating Genes
1 vitiligo-associated multiple autoimmune disease susceptibility 1 13.1
2 deafness, congenital, with vitiligo and achalasia 12.6
3 alopecia universalis onychodystrophy vitiligo 12.4
4 vitiligo, progressive, with mental retardation and urethral duplication 12.3
5 spastic paraplegia 23, autosomal recessive 12.2
6 autoimmune disease 1 12.1
7 alopecia areata 11.8
8 alezzandrini syndrome 11.7
9 autoimmune disease 2 11.6
10 autoimmune disease 3 11.6
11 autoimmune disease 4 11.6
12 schrander-stumpel theunissen hulsmans syndrome 11.6
13 vogt-koyanagi-harada disease 11.6
14 autoimmune polyendocrine syndrome, type i, with or without reversible metaphyseal dysplasia 11.6
15 autoimmune polyglandular syndrome type 3 11.6
16 halo nevus 11.5
17 hypoadrenocorticism, familial 11.4
18 hemifacial atrophy, progressive 11.4
19 autoimmune atrophic gastritis 11.4
20 stiff-person syndrome 11.3
21 familial cold autoinflammatory syndrome 3 11.3
22 hereditary spastic paraplegia 23 11.2
23 ermine phenotype 11.1
24 combined cellular and humoral immune defects with granulomas 11.1
25 nijmegen breakage syndrome 11.1
26 lelis syndrome 11.1
27 t-cell receptor-alpha/beta deficiency 11.1
28 hypopigmentation of eyelid 11.1
29 gemignani syndrome 11.1
30 pigmentation anomaly of the skin 11.1
31 autoimmune disease 10.9
32 skin disease 10.8
33 alopecia 10.8
34 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.7
35 psoriasis 10.7
36 pustulosis of palm and sole 10.7
37 melanoma 10.7
38 melanoma, cutaneous malignant 10 10.6
39 thyroiditis 10.6
40 hypothyroidism 10.6
41 dowling-degos disease 1 10.5
42 dermatitis 10.5
43 dermatitis, atopic 10.5
44 skin carcinoma 10.5
45 hashimoto thyroiditis 10.4
46 halo nevi 10.4
47 lichen planus 10.4
48 thyroid gland disease 10.4
49 pernicious anemia 10.4
50 graves' disease 10.4

Graphical network of the top 20 diseases related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:



Diseases related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Symptoms & Phenotypes for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Human phenotypes related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:

31
# Description HPO Frequency HPO Source Accession
1 vitiligo 31 HP:0001045
2 nevus 31 HP:0003764

Symptoms via clinical synopsis from OMIM:

56
Skin:
vitiligo
halo nevi

Misc:
onset after birth
no predilection for ventral skin

Clinical features from OMIM:

193200

UMLS symptoms related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:


pruritus, exanthema

Drugs & Therapeutics for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Drugs for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 116)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pimecrolimus Approved, Investigational Phase 4 137071-32-0 17753757 6447131
2
mometasone furoate Approved, Investigational, Vet_approved Phase 4 83919-23-7
3
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
4
Tretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4 444795 5538
5 Furocoumarins Phase 4
6 abobotulinumtoxinA Phase 4
7 Cholinergic Agents Phase 4
8 Botulinum Toxins Phase 4
9 Botulinum Toxins, Type A Phase 4
10 Neurotransmitter Agents Phase 4
11
Hyaluronic acid Approved, Vet_approved Phase 3 9004-61-9 53477741
12
Zinc Approved, Investigational Phase 3 7440-66-6 32051
13
Zinc sulfate Approved, Investigational Phase 3 7733-02-0
14
Latanoprost Approved, Investigational Phase 2, Phase 3 130209-82-4 5311221 5282380
15
Tacrolimus Approved, Investigational Phase 2, Phase 3 104987-11-3 445643 439492 6473866
16
Triamcinolone Approved, Vet_approved Phase 2, Phase 3 124-94-7 31307
17 Anesthetics Phase 2, Phase 3
18 Dermatologic Agents Phase 3
19 Insulin, Globin Zinc Phase 3
20 insulin Phase 3
21 Immunosuppressive Agents Phase 2, Phase 3
22 Immunologic Factors Phase 2, Phase 3
23 Calcineurin Inhibitors Phase 2, Phase 3
24 Hormones Phase 2, Phase 3
25 Hormone Antagonists Phase 2, Phase 3
26 glucocorticoids Phase 2, Phase 3
27 triamcinolone acetonide Phase 2, Phase 3
28 Triamcinolone diacetate Phase 2, Phase 3
29 Triamcinolone hexacetonide Phase 2, Phase 3
30
Hydrocortisone Approved, Vet_approved Phase 1, Phase 2 50-23-7 5754
31
Hydrocortisone acetate Approved, Vet_approved Phase 1, Phase 2 50-03-3
32
Simvastatin Approved Phase 2 79902-63-9 54454
33
Etanercept Approved, Investigational Phase 2 185243-69-0
34
Afamelanotide Approved, Investigational Phase 2 75921-69-6
35
Atorvastatin Approved Phase 2 134523-00-5 60823
36
Apremilast Approved, Investigational Phase 2 608141-41-9 11561674
37
Pembrolizumab Approved Phase 2 1374853-91-4
38
leucovorin Approved Phase 2 58-05-9 6006 143
39
Methotrexate Approved Phase 2 59-05-2, 1959-05-2 126941
40
Tofacitinib Approved, Investigational Phase 2 477600-75-2
41
Durvalumab Approved, Investigational Phase 2 1428935-60-7
42
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
43
Bavituximab Investigational Phase 2 648904-28-3
44 Hydrocortisone 17-butyrate 21-propionate Phase 1, Phase 2
45 Hydrocortisone-17-butyrate Phase 1, Phase 2
46 Hydrocortisone hemisuccinate Phase 1, Phase 2
47 Hypolipidemic Agents Phase 2
48 Lipid Regulating Agents Phase 2
49 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 2
50 Anticholesteremic Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 157)
# Name Status NCT ID Phase Drugs
1 Bimatoprost 0.03% Solution, NB-UVB and Fractional Carbon Dioxide Laser in Treatment of Generalized Vitiligo Unknown status NCT03487042 Phase 4 Bimatoprost 0.03% ophthalmic solution
2 Vitiligo and the Koebner Phenomenon (Model of Vitiligo Induction and Therapy: a Clinical and Immunological Analysis) Unknown status NCT01082393 Phase 4 topical tacrolimus treatment;topical pimecrolimus treatment;local mometasone furoate treatment;cold cream
3 Comparison the Efficacy and Safety of 0.1% Tacrolimus Ointment With 0.1% Mometasone Furoate Cream in the Treatment of Adult Vitiligo: A Single Blinded Pilot Study Unknown status NCT01333410 Phase 4 tacrolimus ointment;Mometasone furoate
4 Autologous Punch Grafting in Vitiligo Patients: the Effect of Punchdepth and Punchsize Unknown status NCT01377077 Phase 4
5 Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients: a Randomized Controlled Pilot Study Unknown status NCT01640678 Phase 4
6 Effect of Fluticasone Proprionate 0.05% Cream on Narrow Band UV-B Phototherapy in Active Vitiligo: a Randomised Single Blinded Controlled Trial Unknown status NCT01246921 Phase 4 Fluticasone proprionate 0.05% cream
7 Prospective Open Parallel Right to Left Bilateral Study Comparing Narrowband Ultraviolet B Alone Versus Narrowband Ultraviolet B and Psoralen Plus Ultraviolet A for the Treatment of Vitiligo Completed NCT01732965 Phase 4
8 Botulinum Toxin Treatment for Localized Vitiligo Completed NCT01051687 Phase 4 Botulinum toxin A
9 Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients: a Randomized Controlled Study on the Recipient Site Preparation Completed NCT02458417 Phase 4
10 Effectiveness of Narrow-band Ultraviolet B Combined With Topical Tacrolimus 0.03% in Treatment of Patients With Vitiligo Recruiting NCT03199664 Phase 4
11 Efficacy and Safety of Topical Bimatoprost Solution 0.03% in Stable Vitiligo:A Preliminary Study Withdrawn NCT01202513 Phase 4 Bimatoprost 0.03% topical ophthalmic solution
12 Efficacy of Tacrolimus Ointment 0.1% Versus Placebo in Adults With Facial Non-segmental Vitiligo: a Randomized Double-blind Controlled Study Unknown status NCT02466997 Phase 3 tacrolimus;Placebo
13 Continuative vs Sequential Phototherapy in Non-segmental Vitiligo Patients Unknown status NCT00525395 Phase 3
14 Safety and Efficacy of Melanocyte-keratinocyte Transplantation in the Treatment of Vitiligo Completed NCT00830713 Phase 3
15 Comparative Study of 308nm Excimer Lamp and 308nm Excimer Laser in the Treatment of Vitiligo Completed NCT00696358 Phase 3
16 A Multicenter Double-blind Placebo-controlled Trial of Non-cultured Epidermal Cellular Grafting Versus Hyaluronic Acid for Repigmenting Stable Leukoderma (Vitiligo and Piebaldism) Completed NCT02156427 Phase 3
17 Treatment of Vitiligo With Narrowband UVB (TL01) Combined With Tacrolimus (0.1%) Versus Placebo Ointment, a Randomized Right/Left Double Blind Comparative Study Completed NCT00807690 Phase 3 Tacrolimus ointment
18 Autologous Transplantation of Melanocytes for Treatment of Vitiligo Skin Completed NCT00631865 Phase 3
19 Efficacy and Tolerance of Transplantation of Harvested Epidermal Cells and Narrow-Band UVB in Vitiligo Completed NCT01629979 Phase 2, Phase 3
20 Interest of the Dermabrasion by Laser Erbium in the Treatment of the Vitiligo Completed NCT01087216 Phase 2, Phase 3 Bras B : The group control
21 Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2): A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo Recruiting NCT04057573 Phase 3 Ruxolitinib cream;Vehicle
22 Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1): A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo Recruiting NCT04052425 Phase 3 Ruxolitinib cream;Vehicle
23 Intralesional Candidal Antigen Versus Intralesional Zinc Sulphate in Treatment of Cutaneous Warts, A Randomized Clinical Trial Recruiting NCT03158168 Phase 3 Candida Antigen;Zinc Sulfate
24 Effectiveness of Microneedling and Topical Latanoprost in Treatment of Acrofacial Vitiligo Not yet recruiting NCT03611348 Phase 2, Phase 3 Latanoprost
25 Assessing the Efficacy of Needling With or Without Corticosteroids in the Repigmentation of Vitiligo Terminated NCT02191748 Phase 2, Phase 3 Triamcinolone
26 Maintenance Treatment of Non Segmental Vitiligo With Tacrolimus Ointment 0.1% Versus Control, Randomized and Double Blind Study Terminated NCT01841008 Phase 2, Phase 3 Protopic;Placebo : Diprobase
27 Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Parallel Group Study of the Efficacy and Safety of ACH24 in the Treatment of Vitiligo Withdrawn NCT01419964 Phase 3 Group 01;Group 02
28 Comparative Study of the Use of Trypsin Versus Dispase in Melanocyte-Keratinocyte Transplantation for the Treatment of Vitiligo Withdrawn NCT01822379 Phase 2, Phase 3
29 Treatment and Complication of Bath PUVA in Vitiligo Unknown status NCT00380471 Phase 2
30 Efficacy of Red Light in Vitiligo: A Prospective, Single-Blind Randomized Controlled Trial Unknown status NCT01787708 Phase 2
31 Efficacy and Safety of Intralesional Triamcinolone Acetonide in Vitiligo: A Prospective, Double-Blind Randomized Controlled Trial Unknown status NCT01766609 Phase 2 Triamcinolone Acetonide
32 UVA 1 Phototherapy for Vitiligo Unknown status NCT01787695 Phase 2
33 The Evaluation of Vitiligous Lesions Repigmentation After the Administration of Atorvastatin Calcium Salt and Simvastatin-acid Sodium Salt in Patients With Active Vitiligo (EVRAAS) Unknown status NCT03247400 Phase 1, Phase 2 1% simvastatin-acid sodium salt ointment;1% atorvastatin calcium salt ointment
34 Effectivness of Topical Tacrolimus 0.03% Monotherapy in Patients With Vitiligo: Arandomized Controlled Trial Unknown status NCT03358082 Phase 1, Phase 2 Tacrolimus 0.03% Ointment;Hydrocortisone Acetate 1% Ointment
35 Topical Psoralen Ultraviolet Light A Versus Narrow Band Ultraviolet Light B Treatment for Recalcitrant Dermatoses of the Hand: A Prospective Randomized, Single-blinded Controlled Clinical Trial Unknown status NCT01792245 Phase 2
36 A Phase-II, Randomized, Placebo-controlled Trial of Simvastatin in Generalized Vitiligo Completed NCT01517893 Phase 2 Simvastatin;Placebo
37 Efficacy and Safety of Pimecrolimus for the Treatment of Vitiligo Vulgaris Completed NCT00372307 Phase 2 Application of pimecrolimus
38 Pilot, Investigator-Initiated, Proof-of-Concept, Study of the Efficacy and Safety of Etanercept (Enbrel) in Adults With Vitiligo Completed NCT00134368 Phase 2 Etanercept
39 A Phase II Randomised Pilot Study to Compare the Efficacy and Safety of Subcutaneous, Bioresorbable Afamelanotide Implants and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo Completed NCT01382589 Phase 2 Afamelanotide
40 Open Label Phase 2 Proof-of-concept Pilot Trial of Topical Ruxolitinib in Repigmenting Adult Patients With Vitiligo Completed NCT02809976 Phase 2 Ruxolitinib 1.5% Phosphate Cream
41 Study of Applications of Autologous Epidermal Cells in Liquid Phase in the Treatment of Vitiligo Completed NCT01511965 Phase 1, Phase 2
42 Phase I-II, Randomized, Intraindividually Placebo Controlled Clinical Trial, to Evaluate the Efficacy of Autologous Melanocyte Transplantion on Amniotic Membrane as a Substrate for Patients With Stable Vitiligo. Completed NCT01701648 Phase 1, Phase 2
43 Atorvastatin in Active Vitiligo: a Bicentric Prospective Randomized Trial Completed NCT02432534 Phase 2 Atorvastatin
44 A Split Body Study of the Effects of Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo Completed NCT03123016 Phase 2 Apremilast
45 Repigmentation Using Apremilast and Phototherapy In Diffuse VITILIGO RAPID VITILIGO Completed NCT03036995 Phase 2 Apremilast
46 A Phase 2a, Randomized, Double-Blind, Vehicle-Controlled Study to Assess the Safety, Tolerability, and Systemic Exposure of Cerdulatinib Gel, 0.37% in Adults With Vitiligo Recruiting NCT04103060 Phase 2 Cerdulatinib 0.37% gel;Vehicle gel
47 A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy Recruiting NCT03076554 Phase 2 Avelumab
48 A Phase II Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma Recruiting NCT03519997 Phase 2 Pembrolizumab;Bavituximab
49 A Randomized, Double-Blind, Dose-Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo Active, not recruiting NCT03099304 Phase 2 Ruxolitinib cream;Vehicle cream
50 An Open-Label Pilot Study of the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered Twice-Daily in Adult Subjects With Non-Segmental Facial Vitiligo Active, not recruiting NCT03468855 Phase 2 ATI-50002 topical solution

Search NIH Clinical Center for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Methoxsalen
monobenzone
Trioxsalen

Genetic Tests for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Anatomical Context for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

MalaCards organs/tissues related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:

40
Skin, T Cells, Thyroid, Testes, Liver, Eye, Bone

Publications for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Articles related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:

(show top 50) (show all 6859)
# Title Authors PMID Year
1
Genome-wide association study for vitiligo identifies susceptibility loci at 6q27 and the MHC. 56 61
20526339 2010
2
Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo. 56 61
20410501 2010
3
Vitiligo: complex segregation and linkage disequilibrium analyses with respect to microsatellite loci spanning the HLA. 56 61
11941482 2002
4
The influence of interferon on healthy and diseased skin. 61
30527631 2020
5
A prospective study to assess the efficacy of various surgical modalities in treatment of stable vitiligo patches over resistant sites. 61
32386068 2020
6
Altered expression of nuclear factor of activated T cells, forkhead box P3, and immune-suppressive genes in regulatory T cells of generalized vitiligo patients. 61
31917889 2020
7
Increased risk of endocrine autoimmunity in first-degree relatives of patients with autoimmune Addison's disease. 61
32487775 2020
8
Assessment of suicidal behavior in dermatology (Review). 61
32508997 2020
9
Skin - a vast organ with immunological function (Review). 61
32508987 2020
10
Extensive vitiligo associated to response to c-kit inhibitor in metastatic mucosal melanoma. 61
32011367 2020
11
Diterpenes with potential treatment of vitiligo from the aerials parts of Euphorbia antiquorum L. 61
32234374 2020
12
Proceeding Report of the Second Vitiligo International Symposium-November 9-10, 2018, Detroit, Michigan, USA. 61
31984599 2020
13
Factors affecting the outcome of the suction blisters using two different harvesting techniques in vitiligo patients. 61
31746546 2020
14
Nonsegmental vitiligo follows Blaschko's lines and embryonic pigmentary segments. 61
31898641 2020
15
Genital vitiligo with reticular pigmentation in a male patient. 61
31793664 2020
16
A novel point of care technique to improve graft uptake in melanocyte-keratinocyte transplantation procedure for vitiligo of contoured areas like external ear. 61
32497701 2020
17
Vitiligo expansion and extent correlate with durable response in anti-programmed death 1 antibody treatment for advanced melanoma: A multi-institutional retrospective study. 61
32275100 2020
18
Intracellular virus sensor MDA5 exacerbates vitiligo by inducing the secretion of chemokines in keratinocytes under virus invasion. 61
32532953 2020
19
Comparative study between follicular unit transplantation with intact and unintact hair bulb in treatment for stable vitiligo. 61
32530337 2020
20
Type-1 cytokines regulate MMP-9 production and E-cadherin disruption to promote melanocyte loss in vitiligo. 61
32369451 2020
21
Near-infrared spectroscopy as a potential non-invasive tool in the assessment of disease activity in vitiligo patients. 61
32267028 2020
22
Aberrant ETS-1 signalling impedes the expression of cell adhesion molecules and matrix metalloproteinases in non-segmental vitiligo. 61
32350934 2020
23
Evaluation of the additional effect of topical 5-fluorouracil to needling in the treatment of localized vitiligo. 61
31524967 2020
24
Evidence of a possible therapeutic role of vitamin D in a cohort of adult Caucasian vitiligo patients. 61
31414974 2020
25
The efficacy of fractional carbon dioxide laser combined with narrow-band ultraviolet B phototherapy for non-segmental vitiligo: a systematic review and meta-analysis. 61
32572662 2020
26
The Effect of Isotretinoin on Vitiligo and Autoimmune Comorbidity. 61
32574013 2020
27
NKG2D Defines a Subset of Skin Effector Memory CD8 T Cells with Proinflammatory Functions in Vitiligo. 61
31877315 2020
28
Association study between vitiligo and autoimmune-related genes CYP27B1, REL, TNFAIP3, IL2 and IL21. 61
32282963 2020
29
Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer. 61
32430334 2020
30
Association between immune-related adverse events and efficacy of PD-1 inhibitors in Chinese patients with advanced melanoma. 61
32516130 2020
31
Off-label studies on ruxolitinib in dermatology: a review. 61
32515635 2020
32
It's Not All Sunshine: Non-sun-related Melanoma Risk-factors. 61
32346749 2020
33
Correlation between cutaneous adverse events and prognosis in patients with melanoma treated with nivolumab: A single institutional retrospective study. 61
32162349 2020
34
It Takes Two to Tango. 61
32446332 2020
35
Genome-wide association study identifies CDH13 as a susceptibility gene for rhododendrol-induced leukoderma. 61
32558222 2020
36
Retinal nerve fiber layer, retinal pigment epithelium, and choroidal thickness in vitiligo patients. 61
32515874 2020
37
Afamelanotide implants and narrow-band ultraviolet B phototherapy for the treatment of nonsegmental vitiligo in Asians. 61
31987791 2020
38
Micropunch grafting as an adjuvant for noncultured melanocyte-keratinocyte transplantation for refractory vitiligo. 61
32160974 2020
39
Vitiligo-like depigmentation after chromoblastomycosis: a kind of postinflammatory depigmentation due to fungal infection. 61
32556927 2020
40
Evaluating Population Interest in Vitiligo Through an Analysis of Google Trends and Social Media. 61
32574016 2020
41
Expression of immune checkpoints in active nonsegmental vitiligo: a pilot study. 61
32557594 2020
42
Microdermabrasion and topical tacrolimus: A novel combination therapy of vitiligo. 61
31668003 2020
43
Chemical-Associated Vitiligo. 61
32498770 2020
44
Repigmentation of vitiligo with oral baricitinib. 61
32491188 2020
45
CHARACTERISTICS OF GRAVES DISEASE IN HIV-INFECTED PATIENTS ON ANTIRETROVIRAL THERAPY. 61
31968184 2020
46
Comorbidities in Pediatric Alopecia Areata. 61
32531131 2020
47
Vernonia anthelmintica (L.) Willd.: An ethnomedicinal, phytochemical, pharmacological and toxicological review. 61
32205258 2020
48
Integrative proteomics-metabolomics strategy reveals the mechanism of hepatotoxicity induced by Fructus Psoraleae. 61
32240813 2020
49
Associations of Angiotensin-Converting Enzyme Gene Insertion/Deletion (ACE Gene I/D) Polymorphism With Vitiligo: An Updated Systematic Review and Meta-Analysis. 61
32528781 2020
50
Can we consider silymarin as a treatment option for vitiligo? A double-blind controlled randomized clinical trial of phototherapy plus oral Silybum marianum product versus phototherapy alone. 61
30935260 2020

Variations for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

ClinVar genetic disease variations for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 KIF1B NM_015074.3(KIF1B):c.4387C>T (p.Arg1463Cys)SNV Uncertain significance 374063 rs757850683 1:10425479-10425479 1:10365421-10365421

UniProtKB/Swiss-Prot genetic disease variations for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:

73
# Symbol AA change Variation ID SNP ID
1 PTPN22 p.Arg620Trp VAR_022605 rs2476601

Expression for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Search GEO for disease gene expression data for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6.

Pathways for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

GO Terms for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Sources for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....